Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BLD-0409 with Nintedanib and Pirfenidone in Healthy Volunteers
NCT04939467Phase 1Completed
- Sponsor
- Blade Therapeutics, Inc.
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cudetaxestat in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Blade Therapeutics, Inc. Primary endpoints: Maximum observed drug concentration up to 18 days, Time of maximum drug concentration up to 18 days and 1 more. Started Oct 2021; status: completed.
02
Drugs
cudetaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04939467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939467.